1887
  1. Home
  2. Eurosurveillance
  3. Volume 20, Issue 34, 27/Aug/2015
  4. Article
Perspective Open Access
Like 0
Download

Abstract

Antimicrobial resistance is recognised as a growing problem that seriously threatens public health and requires prompt action. Concerns have therefore been raised about the potential harmful effects of making antibiotics available without prescription. Because of the very serious concerns regarding further spread of resistance, the over-the-counter (OTC) availability of antibiotics was analysed here. Topical and systemic OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway by means of a European survey. We identified a total of 48 OTC products containing 20 different single antibiotics and three antibiotic combinations as active substances, used mainly as topical preparations in short treatment courses. Given the relevance of these medicines and the increasing risk of antimicrobial resistance, it is important to limit the availability of OTC antibiotics and to monitor their use.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2015.20.34.30002
2014-08-27
2024-10-14
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2015.20.34.30002
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/20/34/eurosurv-20-30002-2.html?itemId=/content/10.2807/1560-7917.ES.2015.20.34.30002&mimeType=html&fmt=ahah

References

  1. Reeves D. The 2005 Garrod Lecture: the changing access of patients to antibiotics--for better or worse? J Antimicrob Chemother. 2007;59(3):333-41.  https://doi.org/10.1093/jac/dkl502  PMID: 17289771 
  2. Aronson JK. From prescription-only to over-the-counter medicines (‘PoM to P’): time for an intermediate category. Br Med Bull. 2009;90(1):63-9.  https://doi.org/10.1093/bmb/ldp015  PMID: 19414447 
  3. European Commission. A guideline on changing the classification for the supply of a medicinal product for human use. Revision 2006. Bruxelles: European Commission. [Accessed Sep 2013]. Available from: http://ec.europa.eu/health/files/eudralex/vol-2/c/switchguide_160106_en.pdf
  4. Bond C. The over-the-counter pharmaceutical market – policy and practice. Eurohealth. 2008;14(3):19-24. Available from: http://www.euro.who.int/__data/assets/pdf_file/0016/80440/Eurohealth14_3.pdf
  5. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001;345(11):810-6.  https://doi.org/10.1056/NEJMra011080  PMID: 11556302 
  6. Anekwe L. OTC antibiotic switch halted 'after Government opposition'. London: Pulse. 1 Apr 2010. Available from:http://www.pulsetoday.co.uk/clinical/infectious-diseases/chloramphenicol-use-remains-40-higher-due-to-otc-status/on%20http:/www.pulsetoday.co.uk/otc-antibiotic-switch-halted-after-government-opposition/11028987.article#.UXkC2MqUIWo
  7. ECDC Antimicrobial Resistance and Healthcare-Associated Infections Programme. Antibiotic resistance in Europe: the challenges ahead. Euro Surveill.2009;14(45):pii19405.
  8. Brown NM, Piddock LJ, Dryden MSCouncil of the British Society for Antimicrobial Chemotherapy. European Antibiotic Awareness Day and access to antibiotics. BMJ. 2012;19(345):e7819.  https://doi.org/10.1136/bmj.e7819  PMID: 23166081 
  9. Price C. Chloramphenicol use remains 40% higher 'due to OTC status'. London: Pulse. 26 Apr 2013.Available from: http://www.pulsetoday.co.uk/clinical/infectious-diseases/chloramphenicol-use-remains-40-higher-due-to-otc-status/20002757.article
  10. Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales. Experiences from Sweden 1980-1994. J Clin Pharm Ther. 1996;21(6):423-30.  https://doi.org/10.1111/j.1365-2710.1996.tb00042.x  PMID: 9201570 
  11. Scott G. Over the counter chloramphenicol eye drops. BMJ. 2010;340(feb26 1):c1016.  https://doi.org/10.1136/bmj.c1016  PMID: 20189969 
  12. Davis H, Mant D, Scott C, Lasserson D, Rose PW. Relative impact of clinical evidence and over-the-counter prescribing on topical antibiotic use for acute infective conjunctivitis. Br J Gen Pract. 2009;59(569):897-900.  https://doi.org/10.3399/bjgp09X473132  PMID: 20875257 
  13. European Parliament (EP). European Parliament resolution of 11 December 2012 on the Microbial Challenge – Rising threats from Antimicrobial Resistance (2012/2041(INI)). Strasbourg: EP. 11 Dec 2012. Available from: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2012-0483&language=EN&ring=A7-2012-0373
  14. EuroVoc. Multilingual Thesaurus of the European Union. Domains and MT. 7206 Europe. Luxembourg: Publications Office of the European Union. [Accessed Sep 2013]. Available from: http://eurovoc.europa.eu/drupal/?q=request&mturi=http://eurovoc.europa.eu/100277&language=en&view=mt&ifacelang=en
  15. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011;11(9):692-701.  https://doi.org/10.1016/S1473-3099(11)70054-8  PMID: 21659004 
  16. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.  https://doi.org/10.1086/595011  PMID: 19035777 
  17. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-64.  https://doi.org/10.1086/524891  PMID: 18171244 
  18. World Health Organization (WHO). Critically Important Antimicrobials For Human Medicine, 3rd revision 2011. Geneva: WHO. 2012. Available from: http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf
  19. Actavis UK Ltd. Clamelle. Devon: Actavis UK Ltd. [Accessed Sep 2013] Available from: http://www.clamelle.co.uk/
  20. Scerri J, Monecke S, Borg MA. Prevalence and characteristics of community carriage of methicillin-resistant Staphylococcus aureus in Malta. J Epidemiol Glob Health. 2013;3(3):165-73.  https://doi.org/10.1016/j.jegh.2013.05.003  PMID: 23932059 
  21. Medicines and Healthcare products Regulatory Agency (MHRA). Over-the-counter medicines, Reclassification, List of substances reclassified since 2002, List C, Azithromycin. London: MHRA. [Accessed Aug 2015]. Available from: http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstatusandreclassification/Listsofsubstances/index.htm#l2
  22. Safrany N, Monnet DL. Antibiotics obtained without a prescription in Europe. Lancet Infect Dis. 2012;12(3):182-3.  https://doi.org/10.1016/S1473-3099(12)70017-8  PMID: 22361429 
  23. Grigoryan L, Monnet DL, Haaijer-Ruskamp FM, Bonten MJ, Lundborg S, Verheij TJ. Self-medication with antibiotics in Europe: a case for action. Curr Drug Saf. 2010;5(4):329-32.  https://doi.org/10.2174/157488610792246046  PMID: 20615180 
  24. European Commission (EC). Special Eurobarometer 338. Antimicrobial Resistance Report. Brussels: EC. Apr 2010. Available from: http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_338_en.pdf
  25. Berzanskyte A, Valinteliene R, Haaijer-Ruskamp FM, Gurevicius R, Grigoryan L. Self-medication with antibiotics in Lithuania. Int J Occup Med Environ Health. 2006;19(4):246-53.  https://doi.org/10.2478/v10001-006-0030-9  PMID: 17402220 
  26. Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008;14(1) Suppl 1;33-41.  https://doi.org/10.1111/j.1469-0691.2007.01867.x  PMID: 18154526 
  27. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597-602.  https://doi.org/10.1016/S1473-3099(10)70143-2  PMID: 20705517 
  28. Tängdén T, Cars O, Melhus A, Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010;54(9):3564-8.  https://doi.org/10.1128/AAC.00220-10  PMID: 20547788 
  29. Awad A, Eltayeb I, Matowe L, Thalib L. Self-medication with antibiotics and antimalarials in the community of Khartoum State, Sudan. J Pharm Pharm Sci. 2005;8(2):326-31. PMID: 16124943 
  30. Hadi U, Duerink DO, Lestari ES, Nagelkerke NJ, Werter S, Keuter M, et al. Survey of antibiotic use of individuals visiting public healthcare facilities in Indonesia. Int J Infect Dis. 2008;12(6):622-9.  https://doi.org/10.1016/j.ijid.2008.01.002  PMID: 18396084 
  31. Stelling JM, Travers K, Jones RN, Turner PJ, O’Brien TF, Levy SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis. 2005;11(6):873-82.  https://doi.org/10.3201/eid1106.041160  PMID: 15963282 
  32. Lester SC, del Pilar Pla M, Wang F, Perez Schael I, Jiang H, O’Brien TF. The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med. 1990;323(5):285-9.  https://doi.org/10.1056/NEJM199008023230501  PMID: 2195344 
  33. Alliance for the Prudent Use of Antibiotics. Executive summary: select findings, conclusions, and policy recommendations. Clin Infect Dis. 2005;41(4) Suppl 4;S224-7. PMID: 16032556 
  34. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial consumption in Europe 2010. Stockholm: ECDC; Mar 2013. Available from:http://ecdc.europa.eu/en/publications/Publications/antimicrobial-antibiotic-consumption-ESAC-report-2010-data.pdf
Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Leonard+Both&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Both Leonard</a>, <a href="/search?value1=Radu+Botgros&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Botgros Radu</a>, <a href="/search?value1=Marco+Cavaleri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cavaleri Marco</a></span>. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. <a href="/content/ecdc">Euro Surveill.</a> 2014;20(34):pii=30002. <a href="https://doi.org/10.2807/1560-7917.ES.2015.20.34.30002" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2015.20.34.30002</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 16 Sept 2014;&nbsp;&nbsp; <span class="generated">Accepted</span>: 09 Feb 2015 </span> </p>
/content/10.2807/1560-7917.ES.2015.20.34.30002
/content/10.2807/1560-7917.ES.2015.20.34.30002
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error